Results 131 to 140 of about 3,418,065 (230)

Role of vandetanib in the management of medullary thyroid cancer

, 2012
Maryse Brassard1*, Geneviève Rondeau2* 1Endocrinology Service, Department of Medicine, Centre Hospitalier Universitaire Affilié (CHA), Laval University, Quebec, Canada; 2Endocrinology Service, Department of Medicine, Centre ...
Rondeau G, Brassard M
core  

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, Volume 136, Issue 10, Page 4110-4111, October 2026.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source

Primary synovial sarcoma of the thyroid mimicking medullary thyroid cancer. [PDF]

JCEM Case Rep
Bhuyan SS, Behera KK, Ray S, Sahoo B, Adhya AK, Saikia UN.   +5 more
europepmc   +1 more source

Parathyroid Double Adenoma Associated with Papillary Carcinoma of Thyroid [PDF]

It has been reported that thyroid disease is common in patients with hyperparathyroidism, and vice versa. Parathyroid adenoma is the most common cause of primary hyperparathyroidism (PHPT).
دادخواه, مینو, ایرانپرور, منوچهر, پورفرضی, فرهاد, رستمی, خلیل   +3 more
core  

Targeted therapies in the management of advanced medullary thyroid cancer. [PDF]

Oncologist
Arain HA, Izhar A, Caretti R, Chen H, Vodopivec DM.   +4 more
europepmc   +1 more source

RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases. [PDF]

Cell Rep Med
Bagheri-Yarmand R, Pagnotti GM, Kidd JL, Ramirez DA, Trupti Trivedi, Guerra L, Wang Z, Cruz LM, Moehle JM, Jebaraj YS, Wan X, Song JH, Bassett RL, Lin SH, Hu MI, Sherman SI, Hofmann MC, Guise TA.   +17 more
europepmc   +1 more source

Prognostic Factors in Medullary Thyroid Cancer: A Real-World Study in a Referral Center. [PDF]

Biomedicines
Lauretta R, Puliani G, Terrenato I, Bianchini M, Mormando M, Appetecchia M.   +5 more
europepmc   +1 more source

Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies. [PDF]

Front Endocrinol (Lausanne)
Domenech A, Hopmans M, Barker E, Moss JWE, Carrasco M.   +4 more
europepmc   +1 more source

Laboratory diagnostics and follow-up of medullary thyroid cancer. [PDF]

J Mol Endocrinol
Giovanella L, D'Aurizio F, Petranović Ovčariček P, Hillebrand JJ.   +3 more
europepmc   +1 more source

Pembrolizumab in recurrent or metastatic medullary thyroid cancer. [PDF]

Oncologist
Del Rivero J, Donahue RN, Marte JL, Gramza A, Cordes L, Karzai F, Abel ML, Schlom J, Gulley JL, Madan RA.   +9 more
europepmc   +1 more source